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Severe heart failure has a poor prognosis. Mechanical circulatory support (MCS) is capable of 
assisting the circulation in selected patients to bridge them to heart transplantation or recovery 
of heart function. MCS is manufactured in short-term or long-term designs. Short-term MCS 
can be coupled to an oxygenator to supply oxygen to the blood, and in that case also assist the 
lungs. Short-term MCS is most often extra-corporeal, with the pump situated outside the 
patient’s body and capable of assisting circulation for up to a few weeks. Long-term MCS is 
usually implantable, has batteries to run the pump, and allows the patient to be ambulatory. 
We have investigated different types of circulatory support and its influence on survival, 
possibility for recovery, and ameliorating effects on co-morbidities. 
 
Methods and results 
In the first paper we prospectively studied the possibility of avoiding the need for heart 
transplantation by allowing the hearts of transplant eligible patients to recover function during 
support with a long-term MCS. Eighteen patients were enrolled in the study and each had a 
battery driven long-term MCS implanted into the chest. They were then evaluated for the 
recovery of heart function. Three patients showed signs of recovery and had their long-term 
MCS explanted. Only one of these patients remained well. We conclude that this strategy is 
not applicable to heart transplant candidates in general. 
In the second paper, we retrospectively investigated short-term MCS used for the emergency 
treatment of patients in refractory cardiogenic shock. Fifty-two patients with cardiogenic 
shock were included in the study and were split into two groups: those without previous 
surgery (n=19), and those treated after surgery (n=33). We noted a fairly good survival rate 
(63%) in the group without previous surgery. Patients that had undergone surgery fared less 
well, however, with a 33% survival rate. We believe that most patients would have 
succumbed to circulatory collapse, and from that perspective, the results are encouraging.  
The third paper dealt with the problem of pulmonary hypertension (PH) in heart 
transplantation. Patients with PH treated with or without a long-term MCS implanted before 
heart transplantation were retrospectively reviewed regarding survival and reduction of PH. 
PH was effectively reduced, but no significant difference was seen in survival after heart 
transplantation.  
The final paper is in manuscript. Here, we investigated the results of bridging patients in 
refractory cardiogenic shock to cardiac transplantation with short-term MCS. This strategy 
has been considered to result in inferior survival and is somewhat controversial. Twelve 
patients on short-term assist devices were accepted for transplantation, and transplanted 
without mortality. This is discussed and compared with the bridge-to-bridge concept where 
patients on short-term MCS are implanted with a long-term MCS, and then transplanted.   
Conclusion 
The results of treatment with mechanical circulatory support in patients with severe heart 
failure are encouraging. Mechanical circulatory support can be life saving but demands large 
resources and should be applied to carefully selected patients that could benefit from the 
treatment.
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Abbreviations 
 
AI Aortic insufficiency 
BiVAD Bi-ventricular assist device 
BMI Body mass index 
BSA Body surface area 
BTT Bridge to transplant 
BTB Bridge to bridge  
CI Cardiac index 
CO Cardiac output 
CPB Cardiopulmonary bypass 
CVP Central venous pressure 
ECMO Extra corporeal membrane oxygenation 
EF Ejection fraction 
GFR Glomerular filtration rate 
HLM Heart-lung machine 
Htx Heart transplantation 
IABP Intra-aortic balloon pump 
ICU  Intensive care unit 
LVAD Left ventricular assist device 
LVEDD Left ventricular end diastolic diameter 
MAP Mean arterial pressure 
MCS Mechanical circulatory support 
NO Nitric oxide 
PH Pulmonary hypertension 
PVR  Pulmonary Vascular Resistance 
PCWP Pulmonary capillary wedge pressure 
RRT Renal replacement therapy 
RVAD Right ventricular assist device 
SD Standard deviation 
SEM Standard error of the mean 
SVR Systemic vascular resistance 
TAH Total artificial heart 
TPG Transpulmonary gradient 
VAD Ventricular assist device 
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1. Introduction 
 
Assisting the failing heart with a pump is now an accepted treatment for selected 
patients with life threatening heart failure. Most of today’s patients with long-term 
mechanical circulatory support are awaiting a heart transplant. An increasing number 
will depend on a heart pump for the remainder of their life, or until recovery of heart 
function.  
 
The idea of supporting the human circulatory system has been documented since the 
early nineteenth century. When general surgery had a surge in the latter part of the 
same century, surgery on the heart was viewed as extremely hazardous. Christian 
Theodor Billroth, one of the giants of general surgery, even stated “Any surgeon who 
wishes to preserve the respect of his colleagues, would never attempt to suture the 
heart”. Of Scandinavian interest is that the first recorded successful suturing of the 
heart was at Rikshospitalet, Oslo, by Axel Cappelen on the 4th of September 1895. He 
sutured a knife stab wound in a 24-year old man. With the exception of a few selected 
treatments, such as closed mitral commissurotomy, heart surgery was considered more 
or less impossible until the early 1950s. Several groups conducted experimental work, 
primarily on dogs, to develop the means to perform safe intra-cardiac surgery. 
Examples of ways explored to achieve this goal were deep hypothermia1 and cross-
circulation2. Walt Lillehei and John Lewis in Minneapolis used hypothermia in the 
world’s first recorded successful open-heart surgery on September 2, 1952. 
Eventually, it was the efforts to temporarily replace the function of both the heart and 
lungs with a machine that was to conquer the world of open-heart surgery. The first 
clinical use of a heart-lung machine (HLM) was on April 5, 1951 when Clarence 
Dennis, also in Minneapolis, unsuccessfully tried to close a huge ostium primum 
defect in a 6-year old girl3. The first successful open heart surgery with a HLM was 
performed on May 6, 1953 when John Gibbon in Philadelphia closed an atrial septal 
defect in a 18-year old girl4. This landmark operation soon prompted other centres to 
engage in open-heart surgery with a HLM, and a new era had begun. During the first 
decade of open-heart surgery, severe heart failure during weaning from HLM, or the 
immediate post-operative period, was a major cause of morbidity and mortality. It was 
not until the late 1960s that myocardial protection was discovered to play a major role 
in this devastating complication5. A HLM could also support the circulation of patients 
who had not undergone surgery. In 1957, Jackson Stuckey in New York reported the 
use of a HLM in three patients with acute myocardial infarction (AMI) with 
cardiogenic shock. One of these three patients, who had a systolic arterial pressure of 
less than 70 mm Hg, was saved and could return to normal life6. Attempts at assisting 
the failing heart until recovery were made at several centres who were able to assist 
the heart for up to many hours during the post-operative course7. All systems relied on 
a roller pump or a HLM. With few exceptions, these attempts were unsuccessful. It 
was hypothesised that a longer period of post-operative support, up to several days, 
would improve the possibility of recovery and that a HLM or roller pump could not 
achieve this. The first successful ventricular assist device (VAD) implantation was 
carried out on August 8, 1966 by Michael E DeBakey8. This patient having had an 
unsuccessful predecessor in 19639. The device had a pneumatically driven 
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displacement pump with either intra- or extracorporeal placement and ball valves for 
unidirectional flow. As heart transplantation became a reality after Christiaan Barnard 
performed the first10 on December 3, 1967, the concept of bridge-to-transplantation 
(BTT) was realised. Denton Cooley and colleagues were able to bridge a patient to 
heart transplantation in 197811 with a left ventricular assist device (LVAD) for the first 
time. Another route to salvaging the patient’s life was to completely excise the native 
heart and replace it with a total artificial heart (TAH). Drs. Willem Kolff and Tetsuzo 
Akutsu in Cleveland had, in 1957, been able to support a dog’s circulation for 90 
minutes with a TAH12. On April 4, 1969, the heart of 47-year-old Haskell Karp was 
taken out after an unsuccessful aneurysmectomy and replaced by a TAH in a staged 
procedure, aiming for transplantation. It supported his circulation for 64 hours until a 
donor heart became available and a transplantation was performed 13. As reports of 
mechanical circulatory assist became more abundant, and in general provided positive 
experiences in clinical situations, the National Heart, Lung and Blood Institute 
(NHLBI) became interested. In 1977 the NHLBI issued a grant for the development of 
a LVAD. American government money had already been heavily invested in the 
development of the TAH as part of Lyndon B Johnson’s goal of putting a man on the 
moon and placing an artificial heart in a man before 1970. Up until 2006, for example, 
the National Institute of Health invested more than 400 million US dollars in research 
grants. The new investment resulted in different types of devices, of which the 
Novacor and HeartMate became the best known. Both devices were intracorporeal and 
the Novacor was battery powered, while the HeartMate was pneumatically driven. 
They both proved to be efficient as patients waiting for a heart transplant could now be 
supported until transplantation if they deteriorated on the waiting list. Allowing the 
patient to be ambulatory and able to be discharged from hospital was one of the major 
leaps forward in the field14. Since then, many devices have emerged and there are 
dozens in clinical use and several others under development. Notable improvements 
have been made in making the devices smaller and less traumatic to the blood.  
 
Having a foreign object acting as a pump inside the body and being in contact with the 
bloodstream creates several engineering challenges. The pump has to be durable, 
small, quiet, comfortable, easy to implant, and not too expensive. It is devastating for a 
patient to suffer from stroke, infection, device malfunction, native valve dysfunction or 
bleeding. Before having a device implanted the patient must be evaluated for 
suitability. This selection is crucial to the success of the therapy.  
 
There are many ways to categorise MCS, examples include: intracorporeal vs. 
extracorporeal placement, pulsatile vs. continuous flow and short- vs. long-term use. 
We have chosen to divide our material into two groups: Short- and long-term MCS. As 
the most used long-term MCS is the left ventricular assist device (LVAD), the term 
LVAD is in some parts of the text used more frequently. 
  Introduction  
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Short-term MCS 
 
Indications. A patient with cardiogenic shock refractory to conventional therapy can 
be a candidate for short-term MCS if the individual is likely to 1) have a good chance 
of recovery (e.g. myocarditis, revascularised ongoing myocardial infarction, 
intoxication), 2) be a suitable candidate for heart transplantation or long-term MCS.  
 
Operative technique. Peripheral cannulation. Groin cannulation is usually achieved by 
employing the Seldinger percutaneous technique with a separate cannula for distal 
perfusion. See Figure 1. 
 
 
 
 
 
 
 
Figure 1.  
Schematic  
illustration of 
peripheral  
cannulation technique 
 
 
Central cannulation. If the patient is unlikely to recover quickly it is sometimes 
preferable to assist the left, right or both ventricles separately. See figure 2. This way, 
the caregiver can monitor respiratory status. As most patients in shock have 
predominantly left ventricular failure it is possible to bridge the individual to either a 
heart transplant or a long-term assist device. 
 
 
 
 
 
 
 
 
 
 
Figure 2. 
Schematic  
illustration of 
central cannulation technique 
 
Weaning protocol. Many patients can be weaned from short-term support as their 
illness subsides. To check if the patient is ready to have the pump removed, a 
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meticulous scheme to assess native heart function is mandatory. As the pump speed is 
lowered, haemodynamic and ultrasonographic controls are made to investigate the 
potential recovery. 
 
Anticoagulation protocol. Unfractionated heparin is most commonly used, with APTT 
(activated partial thromboplastin time) or TEG (thromboelastogram) analysis being 
used to monitor anticoagulation levels.  
 
Complications. Bleeding problems or thrombus formations are not uncommon but can 
be managed by adjusting anticoagulation. Malperfusion of the lower extremity is 
avoided by introducing a separate cannula. If end-organ failure does not resolve it can 
be as a result of too late an institution of circulatory support. 
 
Long-term MCS 
 
Indications. The INTERMACS registry (Interagency Registry for Mechanically 
Assisted Circulatory Support) in the USA has defined six levels of decompensation 
in heart failure that lead to the implantation of a long-term MCS15. In short, a 
patient with chronic heart failure will usually decompensate. If this decompensation 
does not resolve or impairs end-organ function, a long-term MCS implantation is 
indicated. Most patients will be eligible for heart transplantation. An increasing 
number of patients will have the device as a permanent solution16. 
 
Operative technique. The most commonly used long-term MCS systems are 
implantable and require access to the heart and large vessels. Although some devices 
are possible to insert via thoracotomy or via the abdomen, most are implanted via 
sternotomy. When the patient is on bypass, the left ventricular apex is incised and the 
inlet to the pump secured. An intra-thoracic pocket is made, the drive-line cable is 
taken out through the skin and the outlet is sutured to the ascending aorta.  
 
Anticoagulation protocol. Antiplatelet drugs and warfarin are the mainstay of 
anticoagulation treatment in long-term MCS. A TEG analysis is made to ensure that an 
adequate reduction of platelet aggregation is achieved. PT (prothrombin time) values 
are commonly aimed at 2-3 INR.  
 
Complications. Bleeding in the perioperative period can be a major concern, 
particularly in the redo situation. Infections, like ventilator associated pneumonia or 
sepsis, are feared complications. Transient renal insufficiency is common, but usually 
resolves as haemodynamic stability is restituted. Device malfunction itself is rare with 
modern devices. Native valve dysfunction can appear late; months or even years after 
surgery and the reason is unknown. As the cardiac ailment reaches the right ventricle, 
right heart failure can develop. Arrhythmia can also be a problem. Driveline infections 
have been reduced with an increased knowledge of handling and dressing.   
  Aims  
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2. Aims of the study 
 
 
 
1. To investigate if it is possible to achieve recovery of the heart in patients with 
advanced heart failure treated with a LVAD in order to avoid heart 
transplantation. 
 
 
2. To investigate if pre-transplant LVAD therapy reduces elevated PVR in patients 
with advanced heart failure.  
 
 
3. To investigate if pre-transplant LVAD therapy in patients with elevated PVR 
and advanced heart failure results in increased survival after heart 
transplantation. 
 
 
4. To investigate if short-term MCS support in patients with refractory cardiogenic 
shock is beneficial. 
 
 
5. To investigate if heart transplantation directly from short-term MCS is feasible 
with acceptable results. 
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3. Materials and methods 
 
Paper I 
 
Paper I studied eighteen consecutive patients receiving a LVAD as a bridge to 
transplantation. The study was performed between September 1997 and June 2002 at 
Sahlgrenska and Lund University Hospitals. The study population consisted of four 
women and 14 men with a mean age of 41 ± 3 (range 19-61) years. The causes of heart 
failure were: DCM (dilated cardiomyopathy) (n=9), myocarditis (n=5), ischaemic 
cardiomyopathy (n=3) and hypertrophic cardiomyopathy (n=1). Despite optimal 
medical treatment, all patients were in NYHA (New York Heart Association) 
functional class IV and had deteriorating renal and/or liver function. A pre-
transplantation evaluation revealed no significant contraindications for heart 
transplantation (Htx) in any patient. After implantation, patients continued to receive 
optimal medical treatment for heart failure, including beta-blockers, ACE-inhibitors 
and spironolactone. During a four-month follow-up period, patients were repeatedly 
evaluated with echocardiography, blood samples and right heart catheterisation. If 
criteria for cardiac recovery were not fulfilled during this period, patients were 
activated on the Htx waiting list.  
 
Paper II 
 
In Paper II, the study population was derived from reviewing the medical records of all 
heart transplant recipients during the time period 1988 – 2007 (n=405), with or 
without PH (pulmonary hypertension) prior to transplant at Sahlgrenska University 
Hospital. Patients underwent routine right heart catheterisations, including 
thermodilution cardiac output measurement, and PH was defined as PVR (pulmonary 
vascular resistance) > 2.5 Wood units and (or) TPG (trans pulmonary gradient) > 12 
mm Hg. Excluded from this analysis were patients undergoing a second heart 
transplantation (n=9), combined heart and kidney transplantation (n=9), children 
younger than 16 years (n=33) or patients who did not have pre-transplantation 
haemodynamic measurements available for analysis (n=48). The number of patients 
included in the study was 148 patients without and 158 patients with PH. Patients with 
PH were divided into two groups, one group included 147 patients with pre-transplant 
elevated PVR (> 2.5 WU) and one group included 11 patients who were pre-treated 
with a LVAD, for patient characteristics see Table 1. The patients with PH and without 
pre-treatment with a LVAD were then stratified into three subgroups: mild PH, 2.5 to 
3.0 WU (n=41); moderate PH, 3.1 to 4.5 WU (n=56) and severe PH, ≥ 4.5 WU (n=50). 
Furthermore, historical controls were selected from the group of patients with PH in 
order to match patients pre-treated with a LVAD in a 2:1 fashion according to the 
following criteria: age ± 10 years, sex, era ± 10 years, underlying diagnosis, PVR 
within subgroup, body surface area (BSA) ± 0.2 m2, body mass index (BMI) < or > 30, 
glomerular filtration rate (GFR) < or > 40 ml/min/1.72 m2, diagnosed diabetes mellitus 
and properties specific for the donor: sex, age and BSA. For patient characteristics see 
Table 2. 
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Table 1. Preoperative data for patients with pulmonary hypertension 
pretreated with LVAD or not. 
Variable  PH no LVAD PH and LVAD 
n  146 11 
Age  years 49±11 46±10 
Male  118 (81%) 10 (91%) 
DCM  66 (45%) 6 (55%) 
IHD  64 (44%) 4 (36%) 
Miscellaneous  16 (11%) 1 (9%) 
PCWP        mmHg 24±6 24±8 
MPAP        mmHg 38±7 37±10 
TPG            mmHg 13±5 15±5 
CI             l/min/ m2 1.7±0.4 1.5±0.4 
PVR           WU 4.3±1.7 4.3±1.6 
Donor age    years 34±13 41±13 
Donor sex male  68% 82% 
Ischaemic time  min 176±51 198±50 
LVAD=left ventricular assist device; WU=wood units; PVR=pulmonary 
vascular resistance; BSA=body surface area; CI=cardiac index; PCWP= 
pulmonary capillary wedge pressure; MPAP=mean pulmonary artery pressure; 
GFR=glomerular filtration rate; IHD=ischemic heart disease. 
 
Table 2. Demographics in patients pre-treated with LVAD prior to  
transplantation and matched controls. 
  LVAD 
(n=11) 
No LVAD  
(n=22) 
p-value 
PVR pre tx  WU 4.3 ± 1.6 4.5 ± 1.8 0.9 
Recipient age years 46± 10 50 ± 10 0.2 
Recipient BSA m2 2.1 ± 0.2 2.0 ± 0.2 0.2 
Ischaemia  min 198 ± 50 188 ± 57 0.6 
Donor age years 41 ± 13 39 ± 14 0.8 
Donor BSA m2 2.0 ± 0.2 1.9 ± 0.2 0.5 
CI l/min/ m2 1.5 ± 0.4 1.5 ± 0.3 0.6 
PCWP mmHg 24 ± 8 27 ± 6 0.1 
MPAP mmHg 37 ± 10 41 ± 6 0.2 
GFR ml/min/1.73 m2 59 ± 20 63 ± 16 0.5 
LVAD=left ventricular assist device; WU=wood units; PVR=pulmonary vascular 
resistance; BSA=body surface area; CI=cardiac index; PCWP=pulmonary capillary 
wedge pressure; MPAP= mean pulmonary artery pressure; GFR=glomerular 
filtration rate. 
Materials and methods 
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Paper III 
 
The third study population consisted of patients receiving short-term MCS with veno-
arterial ECMO (extracorporeal membrane oxygenation) during the years 2000-2007 
(Table 3). Data were collected and reviewed from two institutions (the Sahlgrenska 
and Karolinska University Hospitals). Both these centres have programmes for VADs 
and heart transplantation. Our review was focused on patients with, primarily, acute 
heart failure. Excluded therefore were non-emergent patients (i.e. high-risk cardiac 
interventions such as percutaneous coronary intervention), patients with accidental 
deep hypothermia, and those with a primary pulmonary problem (i.e. lung 
transplantation, adult respiratory distress syndrome, etc). No patients receiving veno-
venous ECMO were included in the study, and patients receiving a LVAD and/or a 
right ventricular assist device (RVAD) were also excluded. This was because 
interpretation of the results would have been even more difficult if acute heart failure 
was mixed with other diagnoses that can be treated with centrifugal circulatory 
support. Elderly patients were not considered for ECMO as heart transplantation was 
the final option in the case of failed recovery, but also due to the experience from the 
SHOCK study reporting dismal results in patients older than 75 years 17. Post-
cardiotomy shock was defined as any need of mechanical assist in a patient recently 
subjected to cardiac surgery. Veno-arterial ECMO support was initiated under the 
following circumstances: 1) acute refractory cardiogenic shock complicating acute 
myocardial infarction, 2) post-cardiotomy cardiogenic shock, 3) immediate post-
transplant cardiac graft failure, 4) aortic aneurysm/acute aortic dissection, 5) 
myocarditis, 6) arrhythmia, 7) miscellaneous conditions. The ECMO was instituted 
either in the catheterisation laboratory or in the operating room. 
 
Table 3. Patient characteristics in patients with cardiogenic shock after surgery (post-
surgery) and in patients who did not undergo surgery (non-surgery). There were 
significantly more patients in the non-surgery group who had acute myocardial 
infarction compared to post-surgery patients, p<0.05. 
 Post-cardiotomy  Non-cardiotomy p-
value* 
Number 33 (63%) 19 (27%)  
Age (years±SD) 52.4 ± 12.7 45.3 ± 18.5 0.11 
     Males (n, %) 31 (94) 13 (68) 0.014 
Reasons for ECMO support, (n, 
%) 
   
    AMI 0 9 (47) < 0.05 
    CABG (incl. ongoing AMI) 10 (30) 0  
    Post htx 5 (15) 0  
    AA/dissection 6 (18) 0  
    Arrhythmia 0 4 (21)  
    Myocarditis 0 2 (11)  
    Miscellaneous 12 (36) 4 (21)  
  Materials and methods  
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Paper IV 
 
The last paper included all consecutive adult or paediatric patients treated with short-
term MCS devices and who underwent cardiac transplantation during support (n=12). 
The study was carried out between the years 2005 and 2009. For comparison, all 
consecutive adult or paediatric patients receiving a second or third generation LVAD 
as bridge-to-transplantation (BTT) during the study period were included in the LVAD 
group (n=18). Patients implanted with pulsatile devices (i.e. Berlin Excor, Syncardia 
TAH, HeartMate I) or patients with the intent of destination therapy were excluded. 
This retrospective review was focused on comparing early and intermediate outcomes 
in patients bridged with a short-term MCS device or a LVAD to cardiac 
transplantation, for patient characteristics see Table 4. 
 
Table 4. Patients characteristics in patients treated  
with short-term MCS (n=12) and LVAD (n=18)  
until heart transplantation. 
Patient characteristics 
Short-term 
MCS  LVAD 
Number of patients 12 18 
   
Male sex, n (%) 10 (83) 16 (89) 
Age, y 38 ± 19 47 ± 13 
CPR, n  1 0 
Intubated, n  7 2 
Renal function   
   Dialysis, n 3 0 
Liver function   
   ASAT (μkat/l) 6.1 ± 13 1.9 ± 4.8 
   ALAT (μkat/l) 5.9 ± 12 2.3 ± 5 
   PT (INR) 2.2 ± 1.2 1.3 ± 0.3 
Blood pressure (mmHg)   
   Systolic 85 ± 16 103 ± 12 
   Diastolic 60 ± 8 65 ± 10 
Heart rate 115 ± 24 82 ± 15 
Central venous pressure (mmHg) 20 ± 3 12 ± 6 
Cardiac Index (l/min/m2) 1.4 ± 0.4 1.9 ± 0.8 
PCWP (mmHg) 26 ± 9 24 ± 8 
ASAT=aspartate aminotransferase, ALAT, ALAT=ala- 
Nine aminotransferas, INR=international normalized 
ratio, PCWP=pulmonary capillary wedge pressure, PT=prothrombin time. 
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Statistics 
 
Paper I 
All data are expressed as the mean ± standard error of the mean (SEM). Comparisons 
between values before implantation and during follow-up were performed with the 
Wilcoxon signed-rank test. A p-value of less than 0.05 was considered significant. 
 
Paper II 
The continuous variables are reported as mean ± standard deviation (SD). To test for 
statistical significance of differences between the groups LVAD treatment or not, the 
Mann-Whitney test was used, except for categorical data for which Fisher’s exact test 
or chi-square was used. The correlation between PVR before the implantation of a pre-
transplant LVAD and PVR during the time on support before transplantation was 
calculated according to Wilcoxon signed-ranked test. Patient survival was calculated 
according to the Kaplan-Meier method and the log-rank-test was used to test the two 
groups. A p-value of <0.05 was considered statistically significant. 
 
Paper III 
The continuous variables are reported as mean ± SD. Early mortality was defined as 
hospital mortality, which is all-cause death within any time interval after the 
mechanical assist operation during first hospital stay, or death within 30 days of 
surgery if the patient was discharged. Observed survival for patients was analysed 
using the life table technique and Kaplan-Meier estimates, and constructed with the 
computer program Statistica. The log-rank test was used to compare the two groups. 
The chi-square test was used to compare categorical variables. A p-value of < 0.05 was 
considered statistically significant. 
 
Paper IV 
The continuous variables are reported as mean ± SD. The chi-square test was used to 
compare groups. Patient survival was calculated according to the Kaplan-Meier 
method and the log-rank test was used to test the two groups. A p-value of < 0.05 was 
considered statistically significant. 
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4. Results 
 
Paper I  
 
All patients survived the surgical procedure. Four patients were re-operated for excessive 
bleeding. The mean LVAD support time was 201 ± 55 days (range 25 - 998 days). During 
LVAD support, all patients normalised their liver and renal function. Sixteen patients were 
discharged from hospital, whereas two remained hospitalised during support. One of these 
patients was transplanted after 20 days and the other was subjected to successful explantation 
after 83 days. Two patients died during LVAD support: one after 97 days due to a malignant 
ventricular arrhythmia (HeartMate VE®), and the other after 90 days due to a technical failure 
in the pump system (Jarvik 2000 VAD®).  
 
Evaluation of heart function. Three patients did not undergo an evaluation of heart 
function during mechanical support. In one patient, Htx was performed before 
evaluation could take place, and another patient developed a significant inflow 
insufficiency with regurgitation of blood from the pump inhibiting rest of the heart. 
One patient fitted with a Jarvik 2000 was totally pump-dependent and showing no 
signs of recovery. The mean time for evaluation of the heart function (the evaluation 
when the final heart function decision was made) for the remaining 15 patients was 76 
days (range, 42–122 days) after implantation of the LVAD.  
 
Right heart catheterisation. The mean CI before implantation was 1.6 ± 0.1 L/min/m2 
and 1.9 ± 0.2 L/min/m2 at the time of evaluation with the LVAD on. There were no 
statistical differences between patients with DCM and patients with other diagnoses. 
PCWP was 22 ± 1.5 mm Hg before implantation of the LVAD and 19 ± 2.3 mm Hg at 
evaluation and demonstrated no statistical significance between the two time periods.  
 
Doppler echocardiography. There was a significant decrease (p<0.005) in LVEDD 
measured by Doppler echocardiography before implantation and at the time of 
evaluation with the pump on (75 ± 0.5 mm and 57 ± 0.6 mm, respectively). There was 
a significant increase in LVEF (left ventricular ejection fraction) from 15.5 ± 1.5% to 
32 ± 5.7% with the pump on  (p<0.001).  
 
Blood analyses. There were no statistical differences in serum levels of MMP-2, 
MMP-9, IL-2, IL-6, TNF-α and NT-proBNP before implantation and at the final 
evaluation when the decision was made for Htx or explantation. 
 
It was only possible to turn off the LVAD in four patients and three of these cases are 
described in detail below and some data are presented in figure 3 and 4.   
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Figure 3.  Three patients, one with dilated cardiomyopathy (DCM), one with giant 
cell myocarditis and one with myocarditis show increased CI at the time of eva- 
luation. Supine exercise of 40 W workload resulted in further increase in cardiac 
index. 
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Figure 4. Three patients, one with dilated cardiomyopathy (DCM), one with 
giant cell myocarditis and one with myocarditis show decreased PCWP at the 
time of evaluation. Supine exercise of 40 W workload did not result in 
significant increase in filling pressure. 
 
1. A 29-year old man presented with acute decompensation due to DCM and was on 
mechanical ventilation and maximal inotropic support. A HeartMate VE was 
implanted. Haemodynamic evaluation after two months revealed a dramatic 
improvement in CI (3.3 L/min/m2) and a LVEF of 45% with a low PCWP (Figure 2 a-
b). The stroke volume was 63 ml. During supine exercise of 40 W workload, CI was 
3.5 L/min/m2, PCWP 19 mm Hg and the stroke volume was 64 ml. The patient had 
borderline haemodynamic data for weaning but after discussion it was decided that the 
device should be explanted. Three days after a successful explantation the patient 
developed cardiogenic shock and a bi-ventricular Abiomed BVS 5000 was implanted 
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as an urgent procedure. After another ten days on temporary support the patient 
underwent a successful Htx.  
 
2. A 22-year old male presented with acute giant cell myocarditis and circulatory 
collapse. He received a HeartMate VE and displayed improvement of heart function 
during the follow-up period. After 65 days of support, CI had risen to 3.3 L/min/m2 at 
rest and increased to 4.5 L/min/m2 during 40 W supine exercises. Further 
measurements showed a decrease in PCWP to 10 mm Hg and normalisation of stroke 
volume to 65 ml (Figure 2 a-b). The patient fulfilled the criteria for weaning. 
However, despite treatment with immunosuppressive medication, the patient 
developed a relapse of giant cell myocarditis resulting in Fontan circulation. The 
patient therefore underwent successful Htx. 
 
3. A 19-year old, previously healthy woman, developed neurological signs of multiple 
sclerosis and shortly thereafter heart failure due to acute myocarditis [10]. The patient 
required mechanical ventilation and a HeartMate VE was implanted in an emergency 
situation. The early post-operative period was uneventful, except for repeated periods 
of septicemia. During evaluation, the heart function showed significant recovery. 
Resting CI, which was found to be 1.8 L/min/m2 at admission, had risen to 3.4 
L/min/m2 (pump off) and LVEF > 50% two months after the implantation of the 
device. During supine exercise with a 40 W workload, the CI measured 4 L/min/m2 
and PCWP 20 mm Hg (Figure 2 a-b). The patient fulfilled the criteria for weaning and 
the device was successfully explanted. Still after eight years of follow-up the heart 
function remains normal with the patient on treatment with beta-blockade and ACE-
inhibitors. 
 
A fourth patient fitted with a Jarvik 2000 showed signs of recovery but refused 
weaning and remained on the pump for 998 days until a successful Htx was 
performed. 
 
Paper II 
 
Pre-treatment with LVAD. The mean age for patients with PH without a LVAD prior 
to transplant was 49 ±11 years and 46 ±10 years in the LVAD group. Thirty-two 
percent were female in the non-LVAD group and 18% in the LVAD group. There 
were no statistical differences between the groups regarding pre-operative data as 
diagnoses, haemodynamic measurements, data on the donors and ischaemic time, 
Table 1. PVR measured at the time of pre-transplant evaluation was 4.3 ± 1.7 WU in 
patients who were transplanted without pre-treatment with a LVAD. In patients who 
were treated with a LVAD, the PVR measured before the implantation of the LVAD 
was 4.3 ± 1.6 WU. PVR was significantly reduced to 2.0  ± 0.6 WU after implantation 
but before transplantation, p <0.05 (Figure 5). Duration of LVAD treatment was 239 
(24-1002) days. One patient, not pre-treated with a LVAD, developed acute right heart 
failure after transplantation requiring mechanical support whereas three LVAD treated 
patients required bi-ventricular mechanical support, none attributable to acute RV 
failure. One patient developed an acute humoral rejection, another had an immediate, 
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massive myocardial infarction and a third patient suffered from primary graft failure, 
all three cases proving fatal.  
 
LVAD treatment vs. matched controls. There were no statistical differences between 
patients pre-treated with a LVAD and matched controls regarding: transplant era ± 10 
years, underlying diagnosis, PVR within subgroup, sex, age ± 10 years, BSA, BMI, 
GFR, diagnosed diabetes mellitus and properties specific for the donor: sex, age and 
BSA. The need for post-operative RRT (renal replacement therapy) was 27% in 
patients not treated with a LVAD and 64% in patients treated with a LVAD prior to 
transplantation (p=0.04). The stay in ICU was 11 days (2-84) in patients without pre-
treatment with a LVAD compared with 8 days (1-30 days) in patients treated with a 
LVAD (p=0.56). The total length of hospital stay was comparable between the two 
groups. See table 5. 
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Figure 5. Pulmonary vascular resistance (Wood units) measured before the 
implantation of a LVAD (1) and during support before transplantation (2). There was a 
significant reduction in pulmonary vascular resistance in patients supported with a 
LVAD, p <0.01.  
 
 LVAD  
(n=11) 
No LVAD 
(n=22)  
p-value 
Post tx RRT 7/11 (64%) 6/22 (27%) 0.04 
Days in ICU post tx 8 ± 9 (1-30) 11 ± 18 (2-84) 0.7 
In-hospital mortality 4/11 (36%) 2/22 (9%) 0.8 
Total length of stay (days) 30± 21 43± 44 0.7 
Post tx mechanical support 3/11 (27%) 1/22 (5%) 0.1 
Table 5. Outcome in patients pre-treated with LVAD prior to transplantation and 
matched controls. 
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All-cause mortality. In patients with PH, there was no significant difference between 
mild, moderate and severe PH in 10-year actuarial survival (p=0.12). The 5-year 
survival was 88%, 63% and 78%, respectively. 
 
Matched LVAD vs. non-LVAD patients. Thirty-day survival for patients in the matched 
non-LVAD group was 91% compared with 82% in patients in the LVAD group. Four-
year survival in patients without prior LVAD treatment was 82% and 64% in patients 
who were treated with a LVAD prior to transplantation (p=0.12) (Figure 6). 
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Figure 6. Survival in patients with pulmonary hypertension transplanted directly 
(n=22) and patients who were supported with a LVAD prior to transplantation (n=11) 
according to Kaplan-Meier. There were no statistically significant differences between 
groups (p=0.12). 
 
 
 
 
 
 
Table 6.  Outcome in post- cardiotomy and non- cardiotomy patients. There were 
significantly more patients in the non- cardiotomy group who underwent pre-ECMO 
CPR compared to patients in the post-cardiotomy group, p< 0.05. 
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Paper III 
 
Fifteen patients (29%) had their assist device inserted during ongoing CPR 
(cardiopulmonary resuscitation). There were significantly more patients with ongoing 
CPR at ECMO institution in the non-cardiotomy group (p=0.025). Eighteen patients 
(35%) had IABP prior to implantation of the centrifugal pump. Survival was 47% in 
the group of patients with on-going CPR and 49% in the group not in need of CPR. 
There was no significant difference in early mortality between patients with CPR 
compared with patients with no CPR at ECMO institution (Table 6). 
 
Mean time on ECMO support for all patients was eight (range 0 - 80) days. Mean time 
on support for the post-cardiotomy group was 5.5 days (1-26 days) and for the non-
cardiotomy group 11.6 days (1-80 days). Two patients had two or more episodes of 
treatment, which were added in the analysis. Twenty-six patients (50%) could be 
weaned from circulatory support. The use of pre-ECMO IABP did not influence 
outcome, weaning rate or mortality. Surviving patients were on ECMO for an average 
of 9.9 days (2-80 days) and non-survivors 5.7 days (1-14 days) (p=0.2). 
 
 
Total (all cause) mortality for all patients was 56% at a mean follow-up time of 2.7 
years. Early mortality was 48%. Early survival in post-cardiotomy patients and non-
cardiotomy patients was 4% and 63%, respectively (p=0.2). There was a tendency 
towards higher long-term survival for patients in the non-cardiotomy group, 63%, 
when compared with the post-cardiotomy group, 33% (p=0.07). The cause of death is 
shown in Table 7. There were no statistical differences regarding survival in patients 
younger or older than 55 years (p=0.47) or cannulation site (p=0.5). There was a 
statistically significant better survival for women (p=0.03). 
 
  
Post-cardiotomy 
 
 
Non-cardiotomy 
 
p-value 
Discharged alive (n, %) 15 (45) 12 (63) n.s. 
Time on ECMO (days ± SD) 5.5 ± 4.9 11.6 ± 17.7 0.068 
Pre-ECMO IABP (n, %) 14 (42) 4 (21) n.s. 
Pre-ECMO CPR (n, %) 6 (18) 9 (47) 0.025 
ICU stay (Days ± SD) 12.8 (1-82) 16.8 (0-58) n.s. 
Post-operative dialysis (n, %) 16 (48) 9 (50) n.s. 
RBC (no, range) 23.3 (0-109) 17.3 (0-55) n.s. 
Re-operation for bleeding (n, %) 18 (55 ) 9 (50) n.s. 
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Table 7.  The cause of death in post-cardiotomy and non-cardiotomy patients treated 
with extracorporeal membrane oxygenation (ECMO). 
 
In the beginning of our series, two patients with femoral cut-down cannulation 
developed severe ischaemia of the lower limb, resulting in amputation. One survived.  
Two patients had severe pulmonary complications that prolonged ECMO treatment but 
did not result in patient death. Mechanical assist was deliberately terminated in two 
patients in whom brain death was diagnosed. The ECMO device in two post-
cardiotomy patients was converted to a long-term left ventricular assist device as a 
bridge-to-heart transplantation and another two patients underwent heart 
transplantation.  
 
Paper IV 
 
Most patients in both groups were men, 10/12 (83%) in the short-term MCS device 
group and 16/18 (89%) in the LVAD group. Patients bridged with a short-term MCS 
device and a LVAD had a mean age of 38 and 47 years, respectively. Seven (58%) of 
the patients in the short-term MCS group were on a ventilator at the time of 
implantation of the support compared with two (11%) in the LVAD group. Three 
patients in the short-term assist device group had renal insufficiency requiring dialysis 
as compared to none in the LVAD group. Two patients in the LVAD group had a 
short-term assist device before LVAD implantation. All LVAD implantations were 
done electively and all of the short-term assist device implants were done emergently. 
Fourteen of the patients in the LVAD group underwent Htx. One patient died on the 
waiting list due to cerebral hemorrhage. Three patients are currently active on the 
waiting list. Three patients in the LVAD group died early post-operatively due to 
cerebral hypoxia, pulmonary embolism and hyper-acute rejection. Eleven patients are 
alive and well after transplantation. In the short-term MCS device group, all patients 
survived the early post-transplant period and could leave hospital. One patient died 
from an unknown cause nine months after transplantation. Early mortality after cardiac 
transplantation in the LVAD and MCS groups was 3/20 (15%) and 0/14 patients, 
respectively. All patients were completely followed-up in this retrospective study.  
 
Perioperative results. In the short-term MCS group, five patients were re-operated for 
bleeding. Mean time on short-term MCS before transplantation was 11.3 (2-30) days. 
The mean post-transplant ICU stay was 15.1 days for the MCS group.  In the LVAD 
 Post-cardiotomy Non-cardiotomy 
No or poor cardiac 
function 
6 1 
Multiorgan failure 8 3 
Severe brain damage 1 3 
Retroperitoneal bleeding 1 0 
Fungal sepsis 1 0 
Vasoplegia 1 0 
Unknown 1 0 
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group, mean post-implant and post-transplant ICU stay was 6.5 (2-45) and 12.5 (2-40) 
days, respectively. The length of stay on the ward post-transplant was 31.8 (1-63) days 
in patients with short-term MCS. In the LVAD group, length of stay on the ward was 
22.3 (0-36) post-implant and 18.5 (0-35) days post-transplant, respectively. See table 8 
and figure 7. 
 
Table 8. Patients characteristics in patients treated with short-term MCS  
(n=12) and LVAD (n=18) until heart transplantation. 
Outcome Short-term MCS LVAD  
n 12 18 
Time on assist, d 11.3 ± 9.6 154 ± 114 
ICU stay, d (post-implant/post-Htx) 15.1 19 (6.5+12.5) 
Ward stay, d (post-implant/post-Htx) 29.6 40.8 (22.3+18.5)
CVL, n, (pre-/post-Htx) 1 3 (2+1) 
Death, n, (pre-/post-Htx) 0 4 (1+3) 
ICU=intensive care unit, CVL=cardiovascular lesions, Htx=heart transplantation 
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Figure 7. Kaplan-Meier survival curve in patients who were supported to heart 
transplantation with short-term mechanical support (n=12) and with left ventricular 
assist device  (n=18) and patients at risk.  
 
Economic calculations. Our cost calculations according to the hospital’s “cost-per-
patient” budgetary system showed that costs for the LVAD and MCS groups were 
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similar with about 3.2 million SEK (Swedish kronor) per patient in total. In the LVAD 
group, implantation amounted to 1.6 million SEK and transplant also 1.6 million SEK. 
In the short-term MCS group, the assist and transplantation occurred during the same 
stay and amounted to an average of 3.2 million SEK per patient.  
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5. Discussion 
 
Paper I 
 
Haemodynamic unloading with LVADs in chronic end-stage heart failure is associated 
with reverse remodelling including favourable changes on a structural, cellular and 
molecular level 18-20.   In addition, reports have emerged showing improvement of 
myocardial function sufficient enough to allow explantation of the supporting device. 
Consequently, treatment with LVADs has been proposed to be a feasible approach to 
bridge selected patients with end-stage heart failure to myocardial recovery and, 
thereby, reduce the need for heart transplantation. 
In the present study, the occurrence of significant cardiac recovery during LVAD 
support was low.  Despite optimal medical heart failure therapy during mechanical 
unloading, none of the patients with chronic end-stage heart failure could be subjected 
to successful weaning from the device. One patient, who suffered from dilated 
cardiomyopathy, fulfilled pre-defined criteria for myocardial recovery and underwent 
explantation, but suffered a relapse a few days later and required re-institution of 
mechanical support. The only patient who could be successfully weaned from the 
device was a young female, who presented with acute cardiogenic shock due to 
fulminant myocarditis. 
Sustained cardiac recovery following mechanical support in patients with dilated 
cardiomyopathy has been described in two publications from the German Heart 
Institute in Berlin 21 22. In 1995, Muller et al. reported functional improvement in five 
(29%) out of 17 patients enabling device explantation, and in 2005, Dandel et al. 
reported successful weaning in 32 (24%) out of 131 patients, who after explantation 
displayed a 78% 5-year survival22.  All patients received medical heart failure 
treatment during unloading. A heart failure history of less than five years, LVEDD < 5 
cm and off-pump LVEF > 45% were predictive of stable recovery.  
In contrast to the findings of the Berlin group, our results do not support the concept of 
LVADs as a bridge to recovery in patients with chronic end-stage heart failure. 
Differences in post-implant treatment cannot explain the discrepancy, since all of our 
LVAD patients received medical heart failure therapy similar to that given in the 
German studies. On the other hand, it is possible that the patient population referred to 
mechanical support may have differed between centres. In the present study 
population, every possible effort was made to treat patients with maximally tolerated 
neurohormonal inhibition before a decision on mechanical support was made, which 
may have lead to a selection of pump recipients with a larger degree of irreversible 
myocardial damage. 
Among the multiple changes that occur within the myocardium after prolonged 
mechanical support, not all appear to be favourable. An observed decrease in myocyte 
area after LVAD implantation has raised concerns over a possible risk of myocardial 
atrophy23. Furthermore, LVAD treatment has been shown to be associated with 
increased myocardial fibrosis resulting in augmented chamber stiffness. These findings 
suggest that cell death with replacement fibrosis continues to take place during 
mechanical support. The observations of the present study are more in line with the 
findings of Mancini et al., who in a retrospective study identified only five (5%) 
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successful explantations among 111 LVAD recipients24. Likewise, our experience is in 
accordance with the study by Helman et al. who reported that heart failure reoccurred 
shortly following explantation in two patients, a phenomenon they termed recurrent 
remodelling25. Thus, in our opinion, patients with long-term end-stage heart failure, 
resistant to adequate medical therapy, are unlikely to display significant recovery 
following treatment with a LVAD. 
The LVAD Working Group Recovery Study was established in response to the 
contrasting reports of functional recovery during LVAD support. In this study, patients 
were assessed both prospectively and monthly with echocardiography during LVAD 
support. Despite observed improvements in cardiac function, none of the patients with 
chronic heart failure demonstrated sufficient cardiac restoration to be weaned from 
LVAD support. 
The possible application of novel pharmacological therapy to facilitate cardiac 
recovery during mechanical support is of interest. The Harefield group has, in addition 
to customary neurohormonal blockade, treated LVAD patients with the β2 agonist 
clenbuterol, which has been shown to induce physiological hypertrophy in the 
myocardium20. It has been suggested that such treatment might improve contractile 
function by changing calcium metabolism at a cellular level. Another potential 
approach would be to develop strategies to modulate the regenerative potential of the 
heart. Such interventions would require implantation of cardiac stem cells and 
promotion of their differentiation into myocytes and coronary vessels, an exciting 
future challenge. 
The role of mechanical circulatory support as a bridge to recovery has not been 
defined. The success rate of such treatment is likely to depend on the degree of 
irreversible myocardial damage at the time of implantation. It is plausible that patients 
with reversible causes of heart failure, such as acute myocarditis, myocardial 
ischaemia or therapy-resistant arrhythmia will show sustained recovery following 
mechanical unloading and, possibly, also patients with heart failure of short duration 
showing signs of ongoing myocardial inflammation. On the other hand, patients with 
heart failure of a longer duration, not responding to adequate medical treatment or 
resynchronisation therapy, are unlikely to display cardiac recovery following 
mechanical circulatory support. Whether novel pharmacological therapy during 
mechanical unloading may facilitate cardiac healing and/or regeneration remains to be 
established. 
 
Paper II 
 
This retrospective, single-centre study describes the effect of unloading the left 
ventricle with a mechanical assist device on elevated PVR in heart transplant 
candidates, prior to orthotopic heart transplantation. Furthermore, we report the 
outcome after heart transplantation in recipients with elevated PVR managed 
according to standard clinical practice to the time of transplant as compared with 
patients subjected to pre-transplant LVAD treatment. The PVR in the group of patients 
treated with a LVAD decreased significantly from elevated level at implant to a 
normal range at the time of transplant. Outcome after heart transplantation was 
comparable with that of matched, pulmonary hypertensive control patients. 
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Furthermore, the study revealed no difference in survival between patients regardless 
of the severity of the elevated PVR. Our study demonstrates that mechanical 
circulatory support effectively reduces an elevated resistance in the pulmonary 
vasculature, in agreement with other reports26 27. It has also been shown that long-term 
post-transplant survival is comparable to patients with normal PVR27. Surprisingly, the 
cohort of patients in the present study, elevated PVR, treated with a LVAD or not, had 
no impact on post-transplant mortality and morbidity. It is also striking that there were 
no differences attributable to the severity of PH. There could be several explanations 
for the observations in this study. First, the decision to implant a LVAD was not 
entirely dependent on the severity of PH in all the studied patients though all had 
elevated PVR. Candidates with PH may present with rapid deterioration in organ 
function and the implantation of a LVAD becomes a high-risk procedure with a 
resultant complicated post-operative course. In this study, we have not presented data 
concerning morbidity at implant but since there were no differences in peri- or post-
transplant morbidity and mortality compared to patients with PH not subjected to 
LVAD treatment, even more or less emergent implants did not affect transplant 
prognosis. However, the significantly higher number of patients in the LVAD group 
requiring RRT (renal replacement therapy) in the immediate post-operative period 
might reflect a somewhat more technically complicated transplant operation. Given the 
fact that these patients are chronically anticoagulated with combinations of several, 
long-acting, potent drugs and are subjected to a re-operation, it is surprising that this 
study did not reveal differences with respect to stay in the ICU or total length of stay. 
The chosen matching criteria in the selection of the control population may have been 
unable to reveal differences between the groups. Another obvious limitation of the 
study is the modest number of patients treated with LVAD, a fact that may have 
affected the investigators ability to recognise important associations owing to 
insufficient power, and thereby masking a positive effect of LVAD treatment of 
patients with PH. 
The normalisation of PVR with LVAD treatment in this group of patients with PH 
may have important implications. Patients with non-reversible PH, not eligible for 
heart transplantation due to an unacceptably high risk of fatal RV failure and a poor 
long-term outcome may be converted to candidates with the same transplant prognosis 
as patients with normal PVR. On the other hand, the data analysis in this study did not 
reveal any impact of elevated PVR on long-term survival post-transplant, regardless of 
classified severity, which is quite inconsistent with other reports. Furthermore, in our 
institution there is the practice of using moderately larger donor hearts for those with 
significant pre-transplant PH, but data analysis in this study revealed that this strategy 
has not been possible to apply. 
 
Our definition of PH was dependent on a calculated value, PVR, assessed in a setting 
where medical therapy was not being actively adjusted. Baseline measurements and 
calculated PVR reflect the patient’s true clinical state at a given time, understanding 
that the haemodynamic state can easily fluctuate with and without medication 
adjustment. At our institution, once the candidate has been accepted for 
transplantation, medical management of the patient’s clinical condition is continued in 
a sometimes more multidisciplinary manner which may, theoretically, optimise the 
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patient resulting in reclassification of mildly elevated PVR into the normal range due 
to pharmacological adjustments. However, associated with time on the waiting list, re-
evaluation of patients with right heart catheterisation is not always necessary and 
improvements with respect to an elevated PVR might pass undetected. On the other 
hand, given the fact that there is a prevailing shortage of donor organs, time awaiting 
transplant might obliterate initial improvement. In this study, the analysed data were 
those obtained closest to the time of heart transplantation. Nevertheless, more than 
50% of included patients had PH and the stratifying with regard to its severity resulted 
in more than 60% being classified with moderate to severe PH (35% and 30%, 
respectively). Thus concluding that included patients were those with more advanced 
heart failure than other studies28, which is consistent with previous reports from this 
institution29. Given this perspective, the impact of elevated PVR on transplant 
prognosis may need to be revisited. This, however, has to be studied further. 
It has been stated that RV dysfunction after cardiac transplantation is primarily related 
to status of the donor heart30. The donor RV is exposed to factors associated with brain 
death and organ preservation detrimental to its mechanical performance well before 
facing an increased afterload in the recipient. This single-centre experience has been 
subjected to evolving new techniques and strategies for almost 20 years, including a 
change in preservation solution and cardioplegia that may have affected the outcome.  
Heart transplantation in patients with fixed, severe PH is contraindicated but 
sometimes it is difficult to determine the degree of reversibility in PVR. Therefore, a 
final option to evaluate reversibility could be LVAD therapy and, in case of 
irreversible PH, heart transplantation is contraindicated. 
In conclusion, treatment with a LVAD prior to transplantation reduces elevated PVR 
in heart transplant recipients, and there was no statistically significant difference in 
short-term or long-term survival between patients with PH managed according to 
standard clinical practice or pre-treated with a LVAD. LVAD therapy for elevated 
PVR in heart transplant candidates emerges as an option but further studies are 
required and the cut-off value in PVR for LVAD therapy remains to be established. 
Furthermore, there was no correlation in long-term survival and the severity of PH. 
 
Paper III 
 
This retrospective, two-centre study, describes the effect of treatment with veno-
arterial ECMO in patients in refractory cardiogenic shock. An important finding in this 
study was the surprisingly high survival rate, despite an expected poor prognosis. In 
addition, initiation of ECMO in the moribund post-cardiotomy patients resulted in a 
higher survival than expected from clinical experience31-33. The number of long-term 
survivals is, to our knowledge the highest reported to date. There could be several 
reasons for these good results. One could be the selection of patients receiving ECMO. 
Recently, Chen et al. presented relatively poor survival rates of critically sick patients 
with AMI and refractory cardiogenic shock where ECMO was initiated during CPR34. 
On the other hand, almost half of the patients with ongoing CPR in our cohort of 
patients survived. Our study period is also more recent than the one described by Chen 
et al., gaining advantage by the rapid developments in pump technology and the 
properties of cannulas etc, which also could explain the improved outcome. 
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Acute myocardial infarction and cardiogenic shock is seen in approximately 10% of 
cases admitted to the emergency room and is hence a fairly common situation. Without 
aggressive treatment, cardiogenic shock results in high mortality35. The survival in 
patients needing a post-cardiotomy assist device, such as a LVAD or ECMO has 
previously been reported to be dismal and nearly always inferior to survival after 
cardiogenic shock of non-cardiotomy aetiology31-34. Our study is well in accordance 
with these findings and shows that short-term circulatory assist can result in 
approximately 50% survival of patients who would otherwise have succumbed. Most 
publications, however, include patients with a wide variety of diagnoses, and elective 
and emergent patients are mixed together with those with primary pulmonary 
problems. The reports also contain different approaches to support the failing heart, i.e. 
LVAD, RVAD and ECMO.  
 
Another important finding was that if the patient survived the early post-operative 
period long-term survival was excellent. This further supports an aggressive treatment 
of patients with cardiogenic shock in non-cardiotomy patients and stresses the need 
and importance of having an organisation trained for the quick initiation of circulatory 
support. An increased survival was also noted for female sex. This could in part be 
explained by the fact that there were only two females in the post-cardiotomy group. 
The time from refractory cardiogenic shock to initiation of ECMO is very important 
and has been shown to be a risk factor for mortality34 36. The risk for severe 
neurological damage increases in a time-dependent manner during CPR and therefore 
it is important to start the ECMO as soon as possible. After diagnosing severe brain 
damage in several patients who came to our hospital under CPR we now only consider 
ECMO in patients with in-hospital-witnessed cardiac arrest. 
 
There are several therapeutic options for the rescue of critically ill patients depending 
on the clinical situation. Patients with AMI complicated with cardiogenic shock are 
treated conventionally with vasopressors and IABP support followed by angioplasty or 
CABG (coronary artery bypass grafting) depending on the clinical situation and the 
decision of the cardiologist and the surgeon. This regimen has improved survival in 
critically sick patients but mortality is still significant37. Therefore, the timing of when 
to initiate ECMO in patients with refractory cardiogenic shock is difficult to determine 
and remains debateable. There are no controlled studies supporting a specific time of 
when to initiate ECMO and our policy has been to use it in patients refractory to the 
therapeutic algorithm described above. It is unknown if earlier initiation of ECMO 
would improve survival and it has to be considered that ECMO itself is also associated 
with complications, sometimes lethal, due to bleeding, infections, but also technical 
failures. Therefore, randomised studies aimed at the clarification of these issues would 
be of the utmost importance. However, there are ethical problems associated with 
randomisation in a salvage therapy context. Before the era described in this report, our 
strategy was to selectively support the failing ventricle, often ending up with bi-
ventricular support. There are several reasons why we changed our routine in favour of 
veno-arterial ECMO as a circulatory support. One is the rapid development regarding 
the pump technology and the durability of the oxygenators. In an emergent situation it 
is easy to insert an ECMO system without first trying to distinguish between uni- or 
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bi-ventricular failure. Femoral percutaneous cannulation offers an easy approach that 
is preferable to sternotomy in patients with cardiogenic shock. Central cannulation was 
more common in post-cardiotomy patients because of the already opened sternum and 
easy conversion from cardiopulmonary bypass CPB to ECMO. There are some 
advantages with central cannulation compared with peripheral cannulation. Peripheral 
cannulation may cause retrograde perfusion and conflicting flows, forcing the heart to 
pump against retrograde flow, which theoretically could inhibit heart recovery. It is 
therefore important to closely investigate recovery of the heart and initiate the weaning 
procedure at an optimal time. 
The duration of ECMO in our patients was longer when compared with those 
described in other studies33 34 36-40. It was most obvious in the non-cardiotomy group; a 
finding also reported by other study groups36. Our strategy was to provide sufficient 
time for the heart to recover from myocardial injury. The shorter duration on ECMO 
support in post-cardiotomy patients was due to the lack of recovery in this very sick 
patient group. When there was no or very poor heart function after 4-5 days, the 
ECMO-treatment was electively terminated.  
 
It has been proposed that a LVAD would be an appropriate treatment option for 
patients in acute cardiogenic shock39. The results reported in the literature are however 
not promising and it seems a better option to use temporary mechanical circulatory 
support in an emergency situation for stabilisation of the circulation, also allowing 
time for further evaluation of the total patient situation. In our experience, some 
patients on temporary mechanical support have been diagnosed with a more or less 
severe neurological damage, making a LVAD implantation and/or transplantation 
contraindicated. Patients who were declared brain-dead became organ donors. On the 
other hand, with improved LVAD technology the use of a LVAD may become a 
primary therapeutic option in selective post-cardiotomy patients who can not be 
weaned off CPB. 
 
The use of IABP has been shown to be a predictor for better survival in patients with 
refractory cardiogenic shock41. Based on the hypothesis of the beneficial effect of 
additional pulsatile flow, reduction of afterload, and better coronary flow our policy is 
to use IABP routinely in patients undergoing ECMO38. However, only 35% of the 
patients in our material had IABP prior to implantation of mechanical support which, 
consequently, was a deviation from our protocol. The decision to go directly for 
ECMO without previous IABP was based on the individual surgeon’s preference, 
often when IABP was assessed not to be effective enough due to very poor or no 
circulation at all. Our hypothesis needs to be proven in a randomised prospective study 
which, however, would be difficult to perform for ethical reasons. 
 
Malperfusion of the leg resulting in ischaemia may occur with cannulation of the 
femoral artery42. It is therefore of the utmost importance to follow the circulation in 
the cannulated leg. Insufficient circulation due to cannulation was not seen in patients 
who had been percutaneously cannulated, which seems to be a way of limiting distal 
malperfusion. The currently preferred method is to place a separate cannula distally in 
Discussion 
   
32 
the femoral artery before placing the femoral artery cannula percutaneously, thereby 
securing the peripheral circulation of the leg. 
 
Paper IV 
 
Cardiac transplantation directly from ECMO or short-term assist devices has 
historically been considered a last resort as outcomes have been considered to be 
inferior to the more traditional alternative with bridge-to-bridge with a LVAD to heart 
transplantation (Htx)43. In our study population with patients in circulatory shock 
rescued with a short-term assist device, all twelve were successfully bridged to Htx. 
These good results are in contrast with the present common opinion that Htx directly 
from ECMO or short-term assist devices is not to be recommended and that patients 
should instead should be bridged with a LVAD to Htx. The recommendations are in 
concurrence with the ISHLT (international society of heart and lung transplantation) 
registry which shows that pre-transplant need of short-term mechanical assist 
significantly increases 1-year mortality by an odds ratio of more than three 44. 
Although this needs to be taken into account, we believe that these data are based on 
patients bridged with older systems in an earlier era and does not reflect the current 
situation. In the present study, only a small cohort of patients (about 10%) who 
underwent Htx at our institution during the time period chosen were included, but they 
represent the most critically ill individuals. These patients with circulatory collapse 
have close to 100% mortality without rescue with a short-term assist device. As 
mentioned, the most common concept in patients awaiting Htx with circulatory 
collapse is the bridge-to-bridge concept 45. However, from the patient’s perspective, 
the risks of significant morbidity and mortality associated with the implantation of a 
LVAD or total artificial heart (TAH) in individuals on a short-term assist device needs 
to be acknowledged. In our small case series, risks in terms of mortality seem higher 
for patients transplanted from a LVAD compared with short-term MCS, despite the 
fact that the latter were the sickest patients imaginable. It may even be the case that 
there is a survival benefit for patients being transplanted directly from MCS, since they 
do not need to undergo additional surgical procedures.   
 
As technical and care giving improvements have been made, short-term MCS is 
perhaps no longer a contraindication to an urgent cardiac transplantation. Both others 
and ourselves have gained better understanding of who is a good candidate for cardiac 
transplantation from a short-term assist device. We now believe that bridging patients 
with short-term assist devices does not at all preclude these patients from an excellent 
outcome. However, the support time on a short-term assist device is a predictor for 
outcome and the availability of a donor heart is crucial. The time on support is also 
dependent on the patient’s condition; the patient has to be transplantable at the time of 
an available donor. This is not only demanding for the team taking care of the patient 
but also for the patient’s relatives. A long waiting time is also costly; therefore, the 
size of the centre is important. A larger centre performs more transplantations and 
receives more donor offers than a smaller centre.  
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In this report, we compare two different subsets of patients that perhaps cannot be 
compared or handled equally in an algorithm. Patients bridged to Htx with a LVAD 
are more stable and sometimes the indication is to relieve a contraindication to Htx, 
such as kidney failure or high pulmonary vascular resistance. But in the majority of 
LVAD patients, the indication is life-threatening deterioration of heart failure. In the 
majority of MCS patients bridged to heart transplantation, however, the indication is 
life-threatening deterioration of the acute heart failure often presented as cardiogenic 
shock. A more suitable comparison would be patients with bridge-to-bridge, but very 
few patients have been converted from short-term MCS to VADs, making a 
comparison difficult in our centre.  It is possible though to use INTERMACS data for 
comparison. In the most recent report from the registry 46, INTERMACS level 1 
patients reach about 70% three month survival but the majority are still not 
transplanted and a further 5-10% will probably expire in the immediate post-transplant 
period.  
 
Even if we believe that excellent outcomes from transplanting patients from MCS are 
possible we recognise that a major problem with this approach is that many donor 
organisations do not have algorithms for these procedures. To manage direct cardiac 
transplantation from MCS requires a better balance between available donors and 
recipients than that seen in most of the donor systems. In some donor organisations, 
patients with end-stage heart failure never receive a cardiac transplant without first 
having a long-term LVAD. Severely diseased patients will therefore need to be treated 
according to the bridge-to-bridge concept in order to obtain a LVAD, and finally a 
cardiac transplantation, and will suffer from several high risk procedures from which 
not all will survive. Our results suggest that young patients suffering from acute 
cardiogenic shock that recover from multiorgan failure on MCS should be transplanted 
directly without passing by other systems or procedures. To achieve this, we will 
require new rules and regulations in many donor organisations. 
 
Regarding costs for treating these patients, it is possible to estimate that a bridge-to-
bridge concept to cardiac transplantation would increase costs by approximately 1.6 
million SEK. This is to be compared with other reports of costs associated with this 
kind of treatement47. 
 
In conclusion, it is both possible and cost-effective to bridge severely ill heart failure 
patients with short-term MCS to cardiac transplantation with good outcomes. 
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6. Conclusions 
 
1. It was not possible to achieve sustained recovery of the heart in patients 
supported with LVAD.  
 
2.  LVAD therapy reduced elevated PVR effectively.  
 
 
3. LVAD therapy in patients with elevated PVR did not seem to offer significant 
benefits with respect to survival.  
 
 
4. Short-term MCS seemed to improve survival in patients with refractory 
cardiogenic shock, especially in patients without prior surgery. 
 
5. Heart transplantation directly from short-term MCS is feasible with good 
results. 
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7. Study limitations 
 
The follow-up was 100% complete and reliable regarding survival in all papers, 
however, since three of the studies were retrospective there is always a risk of 
underestimating clinical events such as complications and other outcome data. There is 
also a limitation on the number of variables, such as pre-operative haemodynamic and 
laboratory values that could be retrieved from the medical records.  
Managing protocols were evolving during the study period and there was no developed 
algorithm that was followed in advance, rather we came up with practical solutions for 
different patients. These solutions are now being developed as an algorithm but need 
to be tested further. 
As the study populations are small, the risk for type II errors is present. The patients 
are very heterogeneous and have varying diagnoses, with the common denominator of 
having severe heart failure. Age varies substantially and there are no control groups. 
These limitations are inherent in these kinds of studies as MCS is a relatively 
uncommon treatment. 
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9. Sammanfattning på svenska 
 
Hjärtsvikt är ett allvarligt tillstånd som i sin mest avancerade form är livshotande. 
Hjärtpumpar kan hjälpa patienter att överleva fram till återhämtning av hjärtfunktion 
eller hjärttransplantation. Dessa stödpumpar för hjärtat finns att tillgå i många former 
för både korttids och långtidsbruk. Vi har undersökt olika typer av hjärtpumpar och 
deras möjligheter att förbättra patienters tillstånd och överlevnad.  
Metoder och resultat  
I det första delarbetet har vi prospektivt studerat möjligheten att undvika behovet av 
hjärttransplantation genom att se om utvalda patienter kan återfå tillräcklig 
hjärtfunktion med stöd av en inopererad hjärtpump för långtidsbruk. Arton patienter 
inkluderades. Patienterna utvärderades med avseende på återhämtning av 
hjärtfunktion. Tre patienter visade tecken på återhämtning och fick hjärtpumpen 
borttagen. Endast en av dessa patienter förblev välmående. Vi drog slutsatsen att denna 
strategi inte lämpar sig för alla patienter med hjärtpump för långtidsbruk.  
 
Det andra delarbetet studerar patienter som akut fått livshotande hjärtsvikt. Patienterna 
fick behandling med en hjärtpump för korttidsbruk som inkluderar en apparat som 
syresätter blodet. Femtiotvå patienter ingick i studien. Patienterna delades in i två 
grupper. Patienter utan tidigare operation (19 patienter) och patienter som nyligen 
genomgått kirurgi (33 patienter). Vi noterade en relativt god överlevnad på 63 % i 
gruppen utan tidigare operation. Patienter som hade opererats klarade sig sämre med 
33 % överlevande. Vi tror att de flesta patienter skulle ha avlidit utan behandlingen, 
och i det perspektivet är resultaten uppmuntrande.  
  
Delarbete tre behandlade problemet med högt blodtryck i lungkretsloppet hos patienter 
aktuella för hjärttransplantation. Det är beskrivet att behandling med hjärtpump för 
långtidsbruk kan avhjälpa detta tillstånd som anses försämra resultaten vid 
hjärttransplantation. Patienter med högt blodtryck i lungkretsloppet behandlades med 
eller utan hjärtpump för långtidsbruk innan hjärttransplantation och undersöktes för att 
se om blodtrycket i lungkretsloppet minskade. Det höga blodtrycket i lungkretsloppet 
sänktes effektivt, men ingen signifikant skillnad sågs i överlevnad efter 
hjärttransplantation.  
 
I det sista delarbetet undersökte vi hur patienter vars hjärtfunktion inte återhämtade sig 
med hjärtpump för korttidsbruk klarade att bli hjärttransplanterade. Denna strategi med 
hjärttransplantation direkt från hjärtpump för korttidsbruk är något kontroversiell då 
det historiskt ansetts att den medför sämre överlevnad. Tolv patienter som 
hjärttransplanterats direkt från hjärtpump för korttidsbruk granskades. Ingen patient 
avled i samband med transplantation och samtliga kunde skrivas ut till hemmet.   
 
Slutsats 
Behandling med hjärtpumpar kan många gånger vara livräddande för patienter med 
livshotande hjärtsvikt. Det är en resurskrävande metod som bör erbjudas särskilt 
utvalda patienter som kan ha nytta av behandlingen.
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Figures 1 and 2 were taken from an educational material used at our clinic. 
